Abstract 427P
Background
Several important factors affect directly or indirectly the quality of life of women with cancer in India. Several unmet needs were found to be unaddressed. This program aims to empower the patient, improve quality of life and encourage them to actively participate in the healing process. Hospitals and oncologists are challenged to develop programs that support the growing number of cancer patients. Failure to address leads to decreased compliance and outcomes.
Methods
Patients will be enrolled to participate in the introductory half a day program after obtaining informed consent and completing the pre assessment form (physical, psychological and socio-economic domains, along with demography, diagnosis and details of treatment received). Program deals with confidence building tips on grooming, Skin and hair care, management of external prosthesis and wigs, lymphedema prevention, Nutritional advice, De-stressing and relaxation techniques Functional exercises for fitness and rehabilitation through supervised fitness and restorative yoga practices. Following the introductory program women are invited to join the 5 day session. The main intervention during this period is supervised yoga, motivation and counseling, meditative practices, guided relaxation, music, dance therapy. The tools used for assessment pre and post intervention are the assessment questionnaire and Hospital Anxiety and Depression (HADS) scale. Many of the physical problems in these women led to emotional problems such as anxiety and depression hence the HADS scale was used.
Results
370 patients were enrolled in the study-86% of patients had breast cancer. Age ranged between 26-76 years. 75% of patients were below 60 years. 18% of the patients below 40 years had breast cancer. The burden of unmet needs was primarily issues related to appearance, hair loss, skin changes, body image, arm swelling, impairment of cognitive factors and emotional problems like depression, anxiety and worry. The percentage of patients with anxiety and depression pre and post interventionTable:
427P
HADS DEPRESSION SCORE | PRE-INTERVENTION | POST-INTERVENTION |
---|---|---|
BORDER LINE (8-10) | 12.50% | 0% |
ABNORMAL (11-21) | 12.50% | 0% |
HADS ANXIETY SCORE | PRE-INTERVENTION | POST-INTERVENTION |
BORDER LINE (8-10) | 18.80% | 0% |
ABNORMAL (11-21) | 37.50% | 0% |
Conclusions
This preliminary study shows that such unique, multidimensional supportive care programs have a significant impact on quality of life through treatment into survivorship phase.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P.P. Bapsy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract